Innovative Antibody Shows Promise in Cancer Treatment

Swedish researchers have developed a '3-in-1' antibody that targets cancer cells, delivers drugs, and boosts immune response.

The antibody, developed by Uppsala University and KTH Royal Institute of Technology, aims to treat various types of cancer by combining three functions in one.
This precision medicine approach targets neoantigens, specific mutations found only in cancer cells, sparing healthy cells.
Animal studies demonstrated increased survival rates in mice, with some achieving complete remission at higher doses.
The treatment's two-part design allows for large-scale production and rapid customization, potentially reducing cost and time for patient-specific therapies.
Next steps include optimizing production and conducting safety studies before starting human clinical trials.